Systemic lupus erythematosus
RecruitingEvaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study
Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study
- Disease:Systemic lupus erythematosus
- Substances:Litifilimab
Greece- Participants:18–64 years · 65+ years
- Substances:Litifilimab
- Sponsor:Biogen Idec Research Limited













